BNT-221
- Generic Name
- BNT-221
Phase 1 Trial Shows Promise for Personalized T Cell Therapy in Advanced Melanoma
A first-in-human phase 1 trial evaluated BNT221, a personalized neoantigen-specific T cell therapy, in patients with advanced melanoma who progressed after standard treatments. The study demonstrated the feasibility and safety of manufacturing patient-specific T cell products targeting multiple tumor mutations, while providing early evidence of clinical activity.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath